DOCSLIB.ORG

C19) United States 02) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1111111111111111 IIIIII IIIII 111111111111111 111111111111111 IIIII IIIII IIIII 1111111111 11111111 US 20190241665Al c19) United States 02) Patent Application Publication (10) Pub. No.: US 2019/0241665 Al KREEGER et al. (43) Pub. Date: Aug. 8, 2019 (54) METHODS OF INHIBITING METASTASIS IN C07K 16/24 (2006.01) CANCER C12N 15/113 (2006.01) A61K 31/439 (2006.01) (71) Applicant: WISCONSIN ALUMNI RESEARCH (52) U.S. Cl. FOUNDATION, Madison, WI (US) CPC .......... C07K 1612854 (2013.01); A61P 35/04 (2018.01); C07K 16/24 (2013.01); Cl2N (72) Inventors: PAMELA KAY KREEGER, 2310/14 (2013.01); C12N 15/1138 (2013.01); MIDDLETON, WI (US); MOLLY A61K 31/439 (2013.01); C07K 2317/76 JANE CARROLL, MADISON, WI (2013.01); C07K 16/2866 (2013.01) (US); KAITLIN C. FOGG, FITCHBURG, WI (US) (57) ABSTRACT (21) Appl. No.: 16/256,065 As described herein, a method of inhibiting metastasis in (22) Filed: Jan. 24, 2019 cancer includes administering to a human subject diagnosed with a cancer of an organ of the peritoneal cavity a thera­ Related U.S. Application Data peutically effective amount of an inhibitor of CCR5 or P-selectin. Preferably the subject has a tumor positive for a (60) Provisional application No. 62/621,769, filed on Jan. ligand of P-selectin such as a CD24+ or PSGL-1 + tumor. 25, 2018. Analysis of samples from HGSOC patients confirmed increased MIP-1 fJ and P-selectin, suggesting that this novel Publication Classification multi-cellular mechanism can be targeted to slow or stop (51) Int. Cl. metastasis in cancers such as high-grade serous ovarian C07K 16/28 (2006.01) cancer, for example by using anti-CCR5 and P-selectin A61P 35/04 (2006.01) therapies developed for other indications. Patent Application Publication Aug. 8, 2019 Sheet 1 of 36 US 2019/0241665 Al AltemativelyNactivated macrophage Ovarian cancer cell SELP Mesothelial cell ~ FIGURE 1 Pour and cure 1 PDMS 11 mm 14 mm FIGURE 2A Patent Application Publication Aug. 8, 2019 Sheet 2 of 36 US 2019/0241665 Al Seed mesothelial Differentiate Meso/MM cells AAMs co-culture (24 h) Adhesion (3 h) Ovarian cancer cell Cross-Section -I AAM Mesothelial Cell 11 mm FIGURE2B Patent Application Publication Aug. 8, 2019 Sheet 3 of 36 US 2019/0241665 Al Cl) -Q) (..) (/) -(l) (.) rn Q) ...,J::, 0 Cl) Q) 2 FIGURE 3A -MMS +MMS FIGURE 3B Patent Application Publication Aug. 8, 2019 Sheet 4 of 36 US 2019/0241665 Al * OV90 OVCAR5 EE1 -MMs • +AAMs FIGURE 3C Direct Indirect signaling signaling FIGURE 3D Patent Application Publication Aug. 8, 2019 Sheet 5 of 36 US 2019/0241665 Al 100 ~ Q) L. * Q) ..c -0 <( ~ 0 CaOV3 OV90 OVCARS C -AAMs a Direct • +AAMs m Indirect FIGURE3E 2 01 -0 ., -6------- -6 2 log(-AAMs) FIGURE 3F Patent Application Publication Aug. 8, 2019 Sheet 6 of 36 US 2019/0241665 Al * . .c () -0 -0 LL 0 + AAMs FIGURE 3G 10 * OV90 OVCARS mm lsotype ii P~Sel FIGURE 3H Patent Application Publication Aug. 8, 2019 Sheet 7 of 36 US 2019/0241665 Al 100 * * -0 (1) \._ Cl) .r::. "O <( '#. + + ,.. + CaOV3 OV90 OVCAR5 /• lsotype ii/ P--selectin Ab FIGURE 31 Patent Application Publication Aug. 8, 2019 Sheet 8 of 36 US 2019/0241665 Al -AAMs +AAMs ~o~~o5t.() LO 0°'>000'>>cu > ro > 0 0 O O 0 0 PDGFBB IL•1~ MIP-1a. MMP~12 GCSF RANTES Eotaxin TNF<x. IFNy 1Lw9 GM~CSF IL-8 Basic FGF IP-10 IL-17a IL~5 IL-4 IL-12p70 IL-10 IL-7 VEGF IL-6 MCP-1 IL .. 13 1L.. 1ra MIP .. 1f1 MMP-7 z-score -2 2 FIGURE4A Patent Application Publication Aug. 8, 2019 Sheet 9 of 36 US 2019/0241665 Al 100 -0 (],)c (],) Cl) .0 0 0 a 100 Predicted - + AAMs e CaOV3 A OV90 ■ OVCAR5 FIGURE4B ,,,i . MIP .. 1f3 .,,,, IL•13 11 % Adhered :::::, r--::::r,-· -+-----ii-----i PC 1 PC2 FIGURE4C VIP 0 N IL-1 ra IL-13 MIP-1p RANTES IL-8 IL-5 PDGFBB IL-17a Eotaxin IL'"9 IFNv a~ MMP--1 ~ TNFa rn .i;;:. GCSF u IL-10 ~ :::::::::::::::1 IP-10 Basic FGF MM~1it : IL-1p MIP-1a ILM+12p70 ILM06 ~, -<-<-xi MCP ... 1 IL "' 7 F~b ·.:~::::::::::"""""""'::::::::<I~·:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.: .. VEGF IV S99lt'Z0/6JOZ Sil 9£ JO OJ J.l.lQS 6JOZ '8 ·~nv UOffBJ!{qlld UO!JBJ!{ddy JU.lfBd Patent Application Publication Aug. 8, 2019 Sheet 11 of 36 US 2019/0241665 Al * * * lso IL 13 PDGF MlP ra -AAMs • + AAMs FIGURE4E 100 -0 * * 0) * '- (l) .c 1J <( ';$!.0 0 Isa IL 13 PDGF MIP li3 -AAMs • +AAMs FIGURE4F Patent Application Publication Aug. 8, 2019 Sheet 12 of 36 US 2019/0241665 Al A B 5 1 E]J R2Y • a2v N>- a PC1 ~ N 6 0:: -5 1 2 Component PC2 Ca0V3 OVCAR5 C 100 100 * * * "O (1) ~ (1) .c "O <( * * * 0~ lso IL13PDGF MIP lso IL13PDGF MIP IEJ -AAMs Ill +AAMs D E 100 :J' "O 60!400 .€0) ~ * 0.. (1) ---20 .c ~ 5 "O ~ <( I a. -::R.0 ~ CaOV3 OV90 OVCAR5 li3 Veh fl;! MIP-1~ +AAMs FIGURES Patent Application Publication Aug. 8, 2019 Sheet 13 of 36 US 2019/0241665 Al ct.12 * aj Cl) . ..c: (.) -0 0 LL. 0 -AAMs + AAMs 1• lsotype B;/a.J MIP-1f3 Ab FIGURE6A Patent Application Publication Aug. 8, 2019 Sheet 14 of 36 US 2019/0241665 Al 1.5 * 0 -AAMs +AAMs .,. lsotype I MIP-.1 p Ab FIGURE6B Patent Application Publication Aug. 8, 2019 Sheet 15 of 36 US 2019/0241665 Al 20 o~-~~~~~"·--~~~~ 0 1 2 3 1() 10 . 10 10 10 BL 1-H (CD62p) FIGURE 6C A 3 a.. * ~ .c () 32 0 LL 0 0 1 10 100 MIP-1 p (ng/mL) Patent Application Publication Aug. 8, 2019 Sheet 16 of 36 US 2019/0241665 Al FIGURE6D 100 * 1J (D "- (l) .c * 1J <{ 0~ 0 ..........-.. ..... MIP-1 f~ - + + + CaOV3 OV90 OVCAR5 /lll DMSO Bl- KF38789 FIGURE6E Cl 3 iD * Cf) ..c• A t) "O -0 LL. O lsotYpe._,.,-CCR5 Ab Eil Veh - MIP-1~ Patent Application Publication Aug. 8, 2019 Sheet 17 of 36 US 2019/0241665 Al FIGURE6F * ,. !: () "O -0 LL 0 DMSO Maraviroc II Veh fll MIP~1f1 FIGURE6G 5 min 20 min 60 min 240 min FIGURE6H Patent Application Publication Aug. 8, 2019 Sheet 18 of 36 US 2019/0241665 Al ct4 * GJ (/) . ..c t) A. "O A -0 0 LL oMSo LY PD & Veh rmaEGI M*Pf -JJ1A FIGURE 61 ~"-= -=('D ~- 'e -(') ~-· -0=-· "-= =-0- Thr202/Tyr204 Ser473 Thr308 -(') ~-· 0.8 Thr185ffyr187 7 0.3 * -0-· ~ * = a:: ~ ~ w ~ ~ I, !* ___ .,.-.,,.-~--! ~ _.,,.~,,,#-" t ~ r " j..... ·---.... _j ~ t ct: ~ ~ ~ <( *~--- ;;& _______________, __ I w w--::~---~,..JB N a., ---~'%"'., - " - ,. ;!I! ~ a.. ...,.-'3! 0 ,».-.$(.,_- ·i~•·---~--"-·'-'"---111 o__ o "°- Time (min) 240 Time (min) 240 Time (min) 240 r,;_ ('D=­ ('D --ffll---· Veh - -• - MIP-113 - "°-0 t.H FIGURE 6J -O'I cr,;_ N 0 "°-0 -N ~ O'I -O'I u. -> Patent Application Publication Aug. 8, 2019 Sheet 20 of 36 US 2019/0241665 Al A lsotype MIP-1p Ab B 3 (/1 2: Q oj * ~ Cl) .c () '"O 0 fl) LL ~ ~ + lilllll Veh F2J' MIP•1 ~ C LP-9 HUVEC 100 : lsotype eo ""'''"' Veh -IL-4 ao 40 20 ------ BL 1·H (CD62p)------ FIGURE7 Patent Application Publication Aug. 8, 2019 Sheet 21 of 36 US 2019/0241665 Al CaOV3 OV90 OVCAR5 : t1\~ ' 1n1j' ·I()(< ·1 . ·•' lsolype ~ 1\ ~ -CD162 H I i ~ J\ l l ,!t t i \ I,,I \ © I \ D i I lj i \ j f 1 * I \ I \ ~ i \ .1 I ~1 ! l I 1\ 1 / \ ,, !j ., ' ;:, I ~ :< ., ~~ ·, j(,. 1:1 H) J!"J 11/ HJ 1:) .. ,;. H:: ·:rt 1U 1/ ·::/ H} HJ 1 ~i ::": 1/' FIGURE SA CaOV3 OV90 OVCAR5 (/) LO ~ Cl t.) FIGURE 8B Patent Application Publication Aug. 8, 2019 Sheet 22 of 36 US 2019/0241665 Al 4 © R2=0. 9321 C)C: 3 CaOV3,, .cco ,. ,.,,,,. .... "" t-'\ 2 OV90,,,,.,.. V QVCAR5...,., ..... "' 9 OVCAR3 32 ' OVCAH4 0 1 OVCAR8 LL 0 o 500 1000 1500 Norm. Median Fl FIGURE 8C 100 * "O Cl) \... Cl) .c ~ 'cf2. Veh MIP-1f3 Ill siC mtlB siCD24 FIGURE 8D Patent Application Publication Aug. 8, 2019 Sheet 23 of 36 US 2019/0241665 Al OA --0-- Veh er(]) -a- M!P~1f3 I... IJ.. (]) 0:: fa'.'J 0.0 0 2000 Speed (i.tmfrnin) FIGURE SE * FIGURE 8F Patent Application Publication Aug. 8, 2019 Sheet 24 of 36 US 2019/0241665 Al (1) Q. "¢ oa>,N Cl) (..) Ill I ..-... 'q" 'q" N ,❖ Cl 0:: (:, <( -u.._.. (.) J: > I 0 _,~ ca 8 '""" peJe4p\:f % <( Ill Patent Application Publication Aug. 8, 2019 Sheet 25 of 36 US 2019/0241665 Al A B CD24 DAPI AF488 OAP! ('<') > 0 8 0 0 0) OJ > 6 0 If) tr) n:: 0:: <( <( 0> 0 ~ FIGURE 10 Relative Frequency Distribution at 25 ~tUmin 0 -C 0.25 .Q ** ...... vc 0 -....,ttf... 0.20 + M!P18 200 400 Speed (J.tm/sec) FIGURE 11 Patent Application Publication Aug. 8, 2019 Sheet 26 of 36 US 2019/0241665 Al ...... vc .,. MIP1B 200 400 600 800 Speed (µm/sec) FIGURE 12 5 .s(l.) * Cl) .c (.) "O 0 u... 0 Peritoneal Wall Mesentery EE Vehicle li3 MIP-1 p FIGURE 13A Patent Application Publication Aug. 8, 2019 Sheet 27 of 36 US 2019/0241665 Al Peritoneal Wall Omentum Mesentery FIGURE 13B Patent Application Publication Aug. 8, 2019 Sheet 28 of 36 US 2019/0241665 Al u -C'f'i Patent Application Publication Aug. 8, 2019 Sheet 29 of 36 US 2019/0241665 Al FIGURE 14A Vehicle MIP-1~ 500 * N E .......0 (/) 0) (.) VehiclMIP-1 f) FIGURE 14B Patent Application Publication Aug.
Recommended publications
  • Us 8530498 B1 3

    Us 8530498 B1 3

    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT

    WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • (12) United States Patent (10) Patent No.: US 9,062,029 B2 Schadt Et Al

    (12) United States Patent (10) Patent No.: US 9,062,029 B2 Schadt Et Al

    USOO9062O29B2 (12) United States Patent (10) Patent No.: US 9,062,029 B2 Schadt et al. (45) Date of Patent: *Jun. 23, 2015 (54) PYRIMIDINYL PYRIDAZINONE 417/10 (2013.01); C07D 417/14 (2013.01); DERVATIVES C07D 451/06 (2013.01); C07D 453/02 (2013.01); A61 K3I/501 (2013.01); A61 K (71) Applicant: Merck Patent GmbH, Darmstadt (DE) 3 1/506 (2013.01); A61 K3I/5355 (2013.01): (72) Inventors: Oliver Schadt, Rodenbach (DE); Dieter A6IK3I/5377 (2013.01); A61K3I/55 Dorsch, Ober-Ramstadt (DE); Frank (2013.01); A61K 45/06 (2013.01) Stieber, Heidelberg (DE); Andree (58) Field of Classification Search Blaukat, Schriesheim (DE) CPC C07D 403/14: A61K31/506; A61K31/5377 USPC ................... 514/236.5, 252.02:544/123, 298 (73) Assignee: Merck Patent GmbH, Darmstadt (DE) See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 0 days. This patent is Subject to a terminal dis U.S. PATENT DOCUMENTS claimer. 6,242.461 Bl 6/2001 Goldstein 6,403,586 B1 6/2002 Ohkuchi et al. (21) Appl. No.: 14/149,110 8,071,593 B2 12/2011 Schadt et al. 8,173,653 B2 5, 2012 Dorsch et al. (22) Filed: Jan. 7, 2014 8,329,692 B2 12/2012 Schadt et al. 8,580,781 B2 * 1 1/2013 Dorsch et al. ............ 514,217.06 (65) Prior Publication Data 8,658,643 B2 * 2/2014 Schadt et al. .............. 514,236.5 2004/O152739 A1 8, 2004 Hanau US 2014/O128396 A1 May 8, 2014 2004/0259863 A1 12/2004 Eggenweiler et al.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
  • (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer Et Al

    (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer Et Al

    US008716252B2 (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer et al. (45) Date of Patent: May 6, 2014 (54) (METHYLSULFONYL) ETHYL BENZENE (51) Int. Cl. ISONDOLINEDERVATIVES AND THEIR A613 L/70 (2006.01) PHARMACEUTICALUSES A613 L/40 (2006.01) C07H 17/02 (2006.01) (75) Inventors: Peter H. Schafer, Somerset, NJ (US); C07D 209/16 (2006.01) Anthony J. Frank, Easton, PA (US); (52) U.S. Cl. Hon-Wah Man, Princeton, NJ (US); Sai USPC ............. 514/27: 514/416:536/17.4: 548/472 L. Shankar, Chesterfield, NJ (US) (58) Field of Classification Search None (73) Assignee: Celgene Corporation, Summit, NJ (US) See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 0 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 13/518,843 6,667,316 B1* 12/2003 Man et al. ..................... 514,323 (22) PCT Filed: Dec. 21, 2010 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O10/06142O WO WOO1,34606 5, 2001 S371 (c)(1), * cited by examiner (2), (4) Date: Aug. 21, 2012 Primary Examiner — Traviss C McIntosh, III (87) PCT Pub. No.: WO2011/079091 (74) Attorney, Agent, or Firm — Jones Day PCT Pub. Date: Jun. 30, 2011 (57) ABSTRACT (65) Prior Publication Data Provided are (methylsulfonyl)ethyl benzene isoindoline US 2013/O1162O4 A1 May 9, 2013 compounds, and pharmaceutically acceptable salts, Solvates, O O or stereoisomers thereof. Methods of use and pharmaceutical Related U.S. Application Data compositions of these compounds are also disclosed.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Section B Changed Classes/Guidelines Final

    Section B Changed Classes/Guidelines Final

    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
  • Use of Chk2 Kinase Inhibitors for Cancer Treatment

    Use of Chk2 Kinase Inhibitors for Cancer Treatment

    (19) TZZ__ ¥_T (11) EP 1 912 635 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/17 (2006.01) A61K 31/175 (2006.01) 05.03.2014 Bulletin 2014/10 A61K 31/4184 (2006.01) A61P 9/10 (2006.01) A61P 3/10 (2006.01) A61P 35/00 (2006.01) (2006.01) (21) Application number: 06800452.2 A61P 29/00 (22) Date of filing: 27.07.2006 (86) International application number: PCT/US2006/029401 (87) International publication number: WO 2007/016338 (08.02.2007 Gazette 2007/06) (54) USE OF CHK2 KINASE INHIBITORS FOR CANCER TREATMENT VERWENDUNG VON CHK2-KINASEHEMMERN ZUR KREBSBEHANDLUNG UTILISATION D INHIBITEURS DE LA CHK2 KINASE POUR LE TRAITEMENT DU CANCER (84) Designated Contracting States: • CARDELINA, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Walkersville, MD 21793 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • JOBSON, Andrew SK TR Walkersville, MD 21793 (US) (30) Priority: 29.07.2005 US 703556 P (74) Representative: Zacco Denmark A/S Hans Bekkevolds Allé 7 (43) Date of publication of application: 2900 Hellerup (DK) 23.04.2008 Bulletin 2008/17 (56) References cited: (73) Proprietor: The Government of the United States WO-A-03/006426 US-A- 3 560 566 of America as US-A1- 2004 214 857 representedby the Secretary of the Department of Health and Human Services • KORYTNYK W ET AL: "Guanylhydrazones with Rockville, MD 20852 (US) potential antileukemic activity.